Previous close | 2.1000 |
Open | 2.1300 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 8.00 |
Expiry date | 2024-10-18 |
Day's range | 2.1000 - 2.1300 |
Contract range | N/A |
Volume | |
Open interest | 15 |
Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.
Candel's (CADL) CAN-2409 prolongs overall survival in a phase II study for treating patients with advanced non-small cell lung cancer who are non-responsive to immune checkpoint inhibitor therapy.
Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy compared to published results of median overall survival of 11.6 months observed with standard of care docetaxel-based chemotherapy in a similar patient populationCAN-2409 treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers